JPRN-UMIN000013206
Completed
未知
efficacy and safety of Gemcitabine plus nab-paclitaxel in unresectable pancreas cancer - Gemcitabine plus nab-paclitaxel treatment for pancreas cancer
Yokohama City University Hospital Oncology0 sites0 target enrollmentFebruary 20, 2014
Conditionsunresectable pancreas cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- unresectable pancreas cancer
- Sponsor
- Yokohama City University Hospital Oncology
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •other malignant diseases Paformance status 3,4 uncontrolable pleural effusion and/or ascites uncontrolable infection uncontrolable DM past treatment history to pancreas cancer
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
Safety and Efficacy for Gemcitabine plus nab-paclitaxel with MK615 combination therapy in unresected/recurrent metastatic pancreatic cancer.: Phase I/II study (PC(UR-M) GEM/nab-PTX + MK615)pancreatic cancerJPRN-jRCTs061180074FUKUBA Nobuhiko35
Recruiting
Phase 1
Safety and Efficacy for Gemcitabine plus nab-paclitaxel with MK615 combination therapy in unresected/recurrent metastatic pancreatic cancer.: Phase I/II studyunresected/recurrent metastatic pancreatic cancerJPRN-UMIN000035158Shimane University Hospital31
Completed
Not Applicable
Phase I/II study of Gemcitabine plus nab-paclitaxel and intraperitoneal paclitaxel for pancreas cancer with peritoneal metastasisThe patients with pancreatic cancer who have peritoneal metastasis diagnosed by staging laparoscopy or open laparotomy.JPRN-UMIN000018878Study group of pancreatic cancer with peritoneal metastasis48
Recruiting
Not Applicable
Safety and efficacy of nab-paclitaxel plus gemcitabine in the patients with recurrent pancreatic cancer after pancreatectomypancreatic cancerJPRN-UMIN000031203niversity of Yamanashi30
Completed
Phase 2
Phase II study of Gemcitabine + nab-paclitaxel as first-line therapy for locally advanced pancreatic cancerlocally advanced unresectable pancreatic cancerJPRN-UMIN000016852Kurume university school of medicine24